Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

APREA THERAPEUTICS, INC.

(APRE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/15/2021 10/18/2021 10/19/2021 10/20/2021 10/21/2021 Date
5.14(c) 5.28(c) 5.22(c) 5.13(c) 5.24 Last
3 104 195 967 446 843 267 697 119 197 650 Volume
-3.93% +2.72% -1.14% -1.72% +2.14% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -37,3 M - -
Net cash position 2021 56,2 M - -
P/E ratio 2021 -2,92x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -40,5 M - -
Net cash position 2022 59,3 M - -
P/E ratio 2022 -2,91x
Yield 2022 -
Capitalization 109 M 109 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 11
Free-Float 89,9%
More Financials
Company
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The Company's lead product, eprenetapopt (APR-246), is a small molecule p53 reactivator that is in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid... 
More about the company
Ratings of Aprea Therapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about APREA THERAPEUTICS, INC.
10/15APREA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
10/15Aprea Therapeutics, Inc. Announces Resignation of Johan Christenson from the Board of D..
CI
10/05INSIDER SELL : Aprea Therapeutics
MT
09/22INSIDER SELL : Aprea Therapeutics
MT
09/20APREA THERAPEUTICS : Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advan..
AQ
09/20Aprea Therapeutics, Inc. Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) i..
CI
09/20Top Premarket Gainers
MT
09/20APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from S&P Global BMI Index
CI
09/14APREA THERAPEUTICS : to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Soli..
AQ
09/14Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Sol..
CI
08/23NORTH AMERICAN MORNING BRIEFING : Stock Furures -3-
DJ
08/20APREA THERAPEUTICS : JPMorgan Downgrades Aprea Therapeutics to Underweight From Neutral
MT
08/16APREA THERAPEUTICS : HC Wainwright Adjusts Aprea Therapeutics' Price Target to $4 from $6,..
MT
08/16APREA THERAPEUTICS : Berenberg Bank Downgrades Aprea Therapeutics to Hold From Buy Followi..
MT
08/16NORTH AMERICAN MORNING BRIEFING : Weak Chinese -4-
DJ
More news
News in other languages on APREA THERAPEUTICS, INC.
10/05VENTE PAR DES INITIÉS : Aprea Therapeutics
09/22VENTE PAR DES INITIÉS : Aprea Therapeutics
More news
Analyst Recommendations on APREA THERAPEUTICS, INC.
More recommendations
Chart APREA THERAPEUTICS, INC.
Duration : Period :
Aprea Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APREA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 5
Last Close Price 5,13 $
Average target price 4,00 $
Spread / Average Target -22,0%
EPS Revisions
Managers and Directors
Christian S. Schade Chairman, President & Chief Executive Officer
Scott M. Coiante Chief Financial Officer, Secretary & Senior VP
Eyal C. Attar Chief Medical Officer & Senior Vice President
Lars Abrahmsén Chief Scientific Officer & Senior Vice President
Johan Rutger Christenson Independent Director
Sector and Competitors
1st jan.Capi. (M$)
APREA THERAPEUTICS, INC.4.27%109
MODERNA, INC.218.76%134 418
LONZA GROUP AG29.18%59 339
IQVIA HOLDINGS INC.40.38%48 194
SEAGEN INC.-0.17%31 811
CELLTRION, INC.-39.00%25 446